Journal List > Tuberc Respir Dis > v.66(5) > 1001375

Shin, Huh, Kwon, Kim, Ahn, and Chang: A Case of Docetaxel Induced Subacute Cutaneous Lupus Erythematosus

Abstract

Drug-induced subacute cutaneous lupus erythematosus (SCLE) is associated with use of the following classes of medications: anti-hypertensives, anti-cholesterolemia, anti-psychotics, and anti-inflammatory drugs. Docetaxel is an anti-neoplastic agent, which is widely used for treatment of non-small cell lung cancer. Few cases of docetaxel-induced SCLE have been reported in the medical literature. Here, we report the case of a 58-year-old female patient who developed drug-induced SCLE after administration of docetaxel. After 4 cycles of chemotherapy with docetaxel and cisplatin, erythematous skin eruptions developed on the patient's face. Skin biopsies of the eruptions were remarkable for interfacing dermatitis with basement membrane thickening. Immunofluorescent study revealed characteristic features of SCLE, including granular deposition of IgM, C3, and apoptotic bodies along the basement membrane. The skin eruptions resolved gradually after cessation of drug and with the use of topical corticosteroids.

Figures and Tables

Figure 1
Chest computed tomography showed lobulated mass in the right lower lobe (A), PET-CT showed multiple metastatic lesions in the pleura, bones, abdominal lymph nodes (B).
trd-66-380-g001
Figure 2
Erythematous rashes in the cheeks and the ridge of the nose which developed in 14 weeks after chemotherapy.
trd-66-380-g002
Figure 3
Histopathological findings showed dermatitis with basement membrane zone thickening (H&E stain, A: ×40, B: ×200), granular deposition of IgM & C3 along the basement membrane zone and apoptotic bodies (direct immunofluorescence, C: C3, D: IgM).
trd-66-380-g003

References

1. Chen M, Crowson AN, Woofter M, Luca MB, Magro CM. Docetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases. J Rheumatol. 2004. 31:818–820.
2. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol. 2001. 28:1–23.
3. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009. 301:99–105.
4. Vasoo S. Drug-induced lupus: an update. Lupus. 2006. 15:757–761.
5. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009. 301:65–70.
6. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev. 2005. 4:309–314.
7. Rubin RL. Drug-induced lupus. Toxicology. 2005. 209:135–147.
8. Kretz-Rommel A, Rubin RL. Disruption of positive selection of thymocytes causes autoimmunity. Nat Med. 2000. 6:298–305.
9. Stollar BD, Stephenson F. Apoptosis and nucleosomes. Lupus. 2002. 11:787–789.
10. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol. 2000. 58:207–216.
11. Dasanu CA, Alexandrescu DT. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer. South Med J. 2008. 101:1161–1162.
TOOLS
Similar articles